2021 德国临床实践指南:成人睾丸生殖细胞瘤的管理—第I部分

2021-01-07 国外泌尿外科相关专家组(统称) Urol Int.2021;105(3-4):169-180.

德国成人睾丸生殖细胞瘤的管理指南是在德国证据和共识基础上而制定的,分为两部分刊出。本文为该指南的第一部分内容,涵盖了主题背景、方法、流行病学、分类系统、诊断和局部分期治疗建议。

中文标题:

2021 德国临床实践指南:成人睾丸生殖细胞瘤的管理—第I部分

英文标题:

Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I

发布日期:

2021-01-07

简要介绍:

德国成人睾丸生殖细胞瘤的管理指南是在德国证据和共识基础上而制定的,分为两部分刊出。本文为该指南的第一部分内容,涵盖了主题背景、方法、流行病学、分类系统、诊断和局部分期治疗建议。 

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=成人睾丸生殖细胞瘤的管理1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a0b361c0020e0a08, title=2021 德国临床实践指南:成人睾丸生殖细胞瘤的管理—第I部分, enTitle=Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I, guiderFrom=Urol Int.2021;105(3-4):169-180., authorId=0, author=, summary=德国成人睾丸生殖细胞瘤的管理指南是在德国证据和共识基础上而制定的,分为两部分刊出。本文为该指南的第一部分内容,涵盖了主题背景、方法、流行病学、分类系统、诊断和局部分期治疗建议。 , cover=https://img.medsci.cn/2021313/1615649991745_2020535.jpg, journalId=0, articlesId=null, associationId=1156, associationName=国外泌尿外科相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Thu Jan 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>德国成人睾丸生殖细胞瘤的管理指南是在德国证据和共识基础上而制定的,分为两部分刊出。本文为该指南的第一部分内容,涵盖了主题背景、方法、流行病学、分类系统、诊断和局部分期治疗建议。&nbsp;</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=87962, tagName=睾丸生殖细胞瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=87962, guiderKeyword=睾丸生殖细胞瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4040, appHits=86, showAppHits=0, pcHits=303, showPcHits=3954, likes=3, shares=4, comments=21, approvalStatus=1, publishedTime=Sat Mar 13 23:54:01 CST 2021, publishedTimeString=2021-01-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Sat Mar 13 23:40:00 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 19:50:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=成人睾丸生殖细胞瘤的管理1.pdf)])
成人睾丸生殖细胞瘤的管理1.pdf
下载请点击:
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1078338, encodeId=58ba10e833891, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3cdd2184668, createdName=1207ea27m57(暂无昵称), createdTime=Thu Dec 09 09:03:27 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012961, encodeId=1b621012961c8, content=随访, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50e15589174, createdName=ms9000000675597819, createdTime=Mon Aug 30 19:36:58 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008618, encodeId=fe96100861825, content=加油!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Tue Aug 17 09:58:40 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974262, encodeId=5cba9e426203, content=想看完, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:37:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974259, encodeId=66e89e4259a2, content=非常想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:16:58 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-12-09 1207ea27m57(暂无昵称)

    感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1078338, encodeId=58ba10e833891, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3cdd2184668, createdName=1207ea27m57(暂无昵称), createdTime=Thu Dec 09 09:03:27 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012961, encodeId=1b621012961c8, content=随访, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50e15589174, createdName=ms9000000675597819, createdTime=Mon Aug 30 19:36:58 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008618, encodeId=fe96100861825, content=加油!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Tue Aug 17 09:58:40 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974262, encodeId=5cba9e426203, content=想看完, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:37:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974259, encodeId=66e89e4259a2, content=非常想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:16:58 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-08-30 ms9000000675597819

    随访

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1078338, encodeId=58ba10e833891, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3cdd2184668, createdName=1207ea27m57(暂无昵称), createdTime=Thu Dec 09 09:03:27 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012961, encodeId=1b621012961c8, content=随访, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50e15589174, createdName=ms9000000675597819, createdTime=Mon Aug 30 19:36:58 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008618, encodeId=fe96100861825, content=加油!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Tue Aug 17 09:58:40 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974262, encodeId=5cba9e426203, content=想看完, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:37:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974259, encodeId=66e89e4259a2, content=非常想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:16:58 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-08-17 Half

    加油!!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1078338, encodeId=58ba10e833891, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3cdd2184668, createdName=1207ea27m57(暂无昵称), createdTime=Thu Dec 09 09:03:27 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012961, encodeId=1b621012961c8, content=随访, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50e15589174, createdName=ms9000000675597819, createdTime=Mon Aug 30 19:36:58 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008618, encodeId=fe96100861825, content=加油!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Tue Aug 17 09:58:40 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974262, encodeId=5cba9e426203, content=想看完, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:37:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974259, encodeId=66e89e4259a2, content=非常想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:16:58 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-17 liujianping197002

    想看完

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1078338, encodeId=58ba10e833891, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3cdd2184668, createdName=1207ea27m57(暂无昵称), createdTime=Thu Dec 09 09:03:27 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1012961, encodeId=1b621012961c8, content=随访, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50e15589174, createdName=ms9000000675597819, createdTime=Mon Aug 30 19:36:58 CST 2021, time=2021-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008618, encodeId=fe96100861825, content=加油!!!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Tue Aug 17 09:58:40 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974262, encodeId=5cba9e426203, content=想看完, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:37:39 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974259, encodeId=66e89e4259a2, content=非常想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61324170624, createdName=liujianping197002, createdTime=Thu Jun 17 06:16:58 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-17 liujianping197002

    非常想看

    0

拓展阅读

2021 德国临床实践指南:成人睾丸生殖细胞瘤的管理—第Ⅱ部分

国外泌尿外科相关专家组(统称) · 2021-01-22